• Este endereço de email está protegido contra piratas. Necessita ativar o JavaScript para o visualizar.

Artigos Científicos

domingo, 16 abril 2017 14:10

Triple-Bead Mixed Amphetamine Salts (SHP465) in Adults With ADHD: Results of a Phase 3, Double-Blind, Randomized, Forced-Dose Trial

Rate this item
(0 votes)

Glen Frick1,2, Brian Yan1, Lenard A. Adler3

Shire, Lexington, MA, USA
Endo Pharmaceuticals, Malvern, PA, USA
New York University, New York, NY, USA

Journal of Attention Disorders: SAGE Journals

April 16, 2017


Objective: Evaluate the efficacy and tolerability of triple-bead mixed amphetamine salts (MAS) in ADHD.

Method: Adults with ADHD Rating Scale IV (ADHD-RS-IV) total scores ≥32 were randomized to 6 weeks of triple-bead MAS (25, 50, or 75 mg) or placebo. The primary endpoint was ADHD-RS-IV total score change from baseline at end of study (EOS).

Results: Least squares mean (95% confidence interval [CI]) treatment differences for ADHD-RS-IV total score changes from baseline to EOS significantly favored triple-bead MAS (all doses combined: −10.6 [−13.2, −8.0]; p < .0001); there were no significant differences between triple-bead MAS dosages. The most frequently reported TEAEs with triple-bead MAS (all doses combined) included insomnia, decreased appetite, and dry mouth. Mean ± SD pulse and systolic blood pressure increases at EOS were 3.5 ± 10.33 bpm and 0.3 ± 10.48 mmHg with triple-bead MAS (all doses combined).

Conclusion: Triple-bead MAS significantly reduced adult ADHD symptoms; the safety profile was consistent with previous triple-bead MAS studies.

Ver artigo completo...

A Direção da SPDA - Sociedade Portuguesa de Défice de Atenção

Read 139 times Last modified on sábado, 18 abril 2020 11:04
© 2020 SPDA - Sociedade Portuguesa de Défice de Atenção. All Rights Reserved. Design by BID-lab